PROFILE |
 |
ViroPharma knows that there's nothing common about fighting the common cold. The development-stage company dedicates its drug discovery efforts to combating diseases caused by RNA viruses, the culprit of such ailments as the measles, rabies, Ebola, viral meningitis, and the common cold. The company's lead drug candidate, Picovir, licensed from Sanofi-Synthelabo, may treat viral respiratory infection (VRI), a severe form of the common cold, and viral meningitis. Also in its pipeline is a potential therapy for respiratory syncytial virus (RSV), which often leads to pneumonia and bronchiolitis; with partner American Home Products, it is developing a hepatitis C drug.
COMPETITION |
 |
Agouron Pharmaceuticals, Inc. (dossier)
Aviron (AVIR)
MedImmune, Inc. (MEDI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.00
1-Yr. Sales Growth: 1,900.0%
Employees: 149
Revenue per employee: $13,422.82
KEY PEOPLE |
 |
Michel de Rosen
CEO
Vincent J. Milano
CFO
CONTACT INFO |
 |
405 Eagleview Blvd.
Exton, PA 19341
US
Phone: 610-458-7300
Fax: 610-458-7380
Online: Web Site
|